anycloud · Jun 2026
A case study described Ångström AI’s CSP-MACE-Å work, the use of more than 100,000 GPU hours, and claims that the model outperformed Meta’s UMA-OMC on evaluation suites.
Gen AI molecular simulations that reproduce wetlab results
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Ångström AI is a Cambridge-founded, physics-first AI company building molecular simulation software for pharma and biotech. Its platform uses generative AI plus machine-learning interatomic potentials to accelerate or replace wet-lab and DFT-heavy workflows for properties like solubility, lipophilicity, hydration, binding, and crystal structure stability.
Primary product
Physics-informed generative AI molecular simulation platform for drug discovery
Founded
2024
Headquarters
San Francisco, California, United States
Team size
1-10 employees
Industry
Technology, Information and Internet
Sub-industry
Scientific software / molecular simulation
Offices
0 jobs at Ångström AI
Check back later for new openings
Business model
Stage
Seed
Total raised
$500K
Latest round
Seed VC · Sep 2024
Latest amount
$500K
Sep 2024 · Y Combinator
Leadership
Cofounder, CEO
Cofounder, Head of AI
Gábor Csányi
Cofounder, Head of Science
Co-founder
Bálint Máté
Member of Technical Staff
Graeme Day
Advisor
Investors
Research-led and scientifically rigorous, with a customer-centric posture toward pharma/biotech collaboration. Public materials emphasize practical application, academic depth, and fast iteration on simulation research rather than a consumer-product culture.
Pricing
Not publicly disclosed; public materials suggest demo-, pilot-, and partnership-led enterprise sales.
Differentiators
Technology
Customers
Competitors
Estimated revenue
≈$900K ARR (estimated, 2024)
Estimated monthly visits
2.3K
Traffic estimate as of Jun 2026
anycloud · Jun 2026
A case study described Ångström AI’s CSP-MACE-Å work, the use of more than 100,000 GPU hours, and claims that the model outperformed Meta’s UMA-OMC on evaluation suites.
LinkedIn · May 2026
Laurence Midgley announced a collaboration with AstraZeneca on CSP-MACE-Å, describing the model as a DFT-replacement for crystal structure prediction and claiming a 10,000x speedup with comparable accuracy.
AI Insider · Jul 2024
A launch-profile article summarized the company’s mission, team background, MACE technology, and diffusion-model acceleration approach for drug discovery simulations.
Y Combinator
YC’s launch page introduced Ångström AI as a generative-AI molecular simulation company for pharma and biotech, highlighting the team’s Cambridge background and its experimental-accuracy claims.